In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

While both drugs have demonstrated significant weight-loss effects in previous trials ... tolerated dose of tirzepatide (10 or 15 mg; n = 374) or semaglutide (1.7 or 2.4 mg; n = 376) once weekly ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.